GRF — EAGLE CAPITAL GROWTH FUND, INC.
—
NYSE ·
Unknown ·
Unknown ·
CIK 850027 ·
Last close
$9.72
Market Cap
$38.58M
52W High
$11.85
52W Low
$9.41
ADV30
3,113
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 48,359,376 | — | 33,122 |
| Dec 2025 | — | — | — | — | 47,500,636 | — | 64,690 |
| Jun 2025 | — | — | — | — | — | — | — |
| Dec 2024 | — | — | — | — | 45,843,132 | — | 63,108 |
Balance + Analyst (yfinance extras)
Retained Earnings
$23,875,611
Inventory
—
Receivables
$76,182
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$901,549
EBITDA
—
Free Cash Flow
—
Enterprise Value
—
Total Cash
—
Total Debt
$0
Shares Out
3,967,836
Trailing EPS
$1.00
Book Value
$12.18
ROE
8.3%
ROA
0.4%
Div Yield
8.16%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,284,764 | — | 5,028,583 | 47,500,636 | 64,690 | 47,435,946 | — |
| Dec 2024 | 5,800,501 | — | 5,540,862 | 45,843,132 | 63,108 | 45,780,024 | — |
| Dec 2023 | 4,853,149 | — | 4,612,434 | 43,002,015 | 64,726 | 42,937,289 | — |
| Dec 2022 | -1,561,908 | — | -1,805,909 | 39,777,755 | 64,157 | 39,713,598 | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ESAUF | ESGold Corp. | $38.54M | $0.35 | — |
| MIND | MIND TECHNOLOGY, INC | $38.63M | $4.25 | — |
| BZDLF | KINCORA COPPER LTD | $38.41M | $0.80 | — |
| ACCL | Acco Group Holdings Ltd | $38.36M | $2.75 | — |
| AERT | Aeries Technology, Inc. | $38.96M | $7.22 | — |
News headlines (Yahoo Finance, 1h cache)
Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test
2026-07-28 17:09 · Yahoo
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
2026-07-16 12:00 · Yahoo
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
2026-06-15 12:00 · Yahoo
Grifols (BME:GRF) Valuation Check After Mixed Short And Long Term Share Price Performance
2026-05-10 00:23 · Yahoo
Green Rise Announces Certain Management Changes
2026-01-05 22:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.